Coegin Pharma has established its own production facility in Denmark to secure deliveries, production capacity and quality control. Test production began in September and commercial production of Follicopeptide projectproducts started in October 2025. The facility gives the company full control over the production chain and reduces dependence on external partners. CEO Jens Eriksson emphasizes that the decision provides control over production times, quality and costs. The facility enables both commercial production and R&D activities at low cost.
|
Published October 13, 2025
Coegin Pharma establishes its own production facility in Denmark
Text:
News Desk [email protected]
Notes
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account